Robert Pordy Selected Research

alirocumab

10/2022	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.
10/2022	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES.
8/2022	Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
1/2022	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.
1/2022	Alirocumab after acute coronary syndrome in patients with a history of heart failure.
1/2022	Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.
1/2022	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial.
1/2021	Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study.
1/2021	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
1/2021	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert Pordy Research Topics

Disease

27	Acute Coronary Syndrome 10/2022 - 11/2014
16	Myocardial Infarction 10/2022 - 11/2014
15	Unstable Angina 10/2022 - 11/2014
14	Ischemic Stroke 10/2022 - 04/2015
13	Coronary Disease (Coronary Heart Disease) 10/2022 - 04/2015
8	Injection Site Reaction 11/2018 - 07/2012
6	Hypercholesterolemia 01/2021 - 09/2014
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 01/2017
4	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2021 - 10/2016
4	Homozygous Familial Hypercholesterolemia 12/2020 - 11/2019
3	Dyslipidemias (Dyslipidemia) 01/2022 - 01/2019
2	Hypertriglyceridemia 01/2021 - 01/2019
2	Body Weight (Weight, Body) 12/2020 - 01/2020
2	Atherosclerosis 12/2020 - 08/2017
2	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020 - 01/2017
1	Heart Failure 01/2022
1	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 01/2022
1	Atrial Fibrillation 01/2022
1	Neurocognitive Disorders (Clerambault Syndrome) 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Chronic Limb-Threatening Ischemia 01/2020
1	Genetic Risk Score 01/2020
1	Ischemia 01/2020
1	Pulmonary Embolism 01/2020
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2020
1	Peripheral Arterial Disease 01/2020
1	Hemorrhagic Stroke 12/2019
1	Stroke (Strokes) 12/2019
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 12/2019
1	Rare Diseases (Rare Disease) 11/2019
1	Prediabetic State (Prediabetes) 01/2019
1	Diabetes Mellitus 01/2019
1	Chronic Renal Insufficiency 01/2019
1	Pruritus (Itching) 12/2016
1	Diabetes Complications 12/2016
1	Respiratory Tract Infections (Respiratory Tract Infection) 12/2016
1	Myalgia 04/2015

Drug/Important Bio-Agent (IBA)

40	alirocumabIBA 10/2022 - 07/2012
27	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2022 - 09/2014
16	LDL CholesterolIBA 10/2022 - 11/2014
16	oxidized low density lipoproteinIBA 10/2022 - 11/2014
11	omega-Chloroacetophenone (Mace)IBA 10/2022 - 12/2016
10	LipidsIBA 01/2021 - 09/2014
9	Proprotein Convertase 9IBA 08/2022 - 09/2014
8	Monoclonal AntibodiesIBA 01/2021 - 09/2014
7	Lipoproteins (Lipoprotein)IBA 08/2022 - 01/2019
5	evinacumabIBA 01/2021 - 11/2019
5	Lipoprotein(a)IBA 01/2021 - 01/2020
4	Ezetimibe (Zetia)FDA Link 01/2019 - 09/2014
3	ApolipoproteinsIBA 08/2022 - 08/2017
3	Angiopoietin-Like Protein 3IBA 01/2021 - 01/2019
3	LDL Lipoproteins (beta Lipoproteins)IBA 12/2020 - 11/2018
2	Apolipoproteins B (ApoB)IBA 08/2022 - 08/2017
2	AngiopoietinsIBA 01/2020 - 11/2019
2	HDL CholesterolIBA 11/2018 - 08/2017
1	Atorvastatin (Lipitor)FDA Link 01/2022
1	Simvastatin (Zocor)FDA LinkGeneric 01/2022
1	Rosuvastatin Calcium (Crestor)FDA Link 01/2022
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022
1	antineoplaston A10 (A 10)IBA 01/2021
1	SubtilisinIBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 11/2019
1	LDL Receptors (LDL Receptor)IBA 11/2019
1	Triglycerides (Triacylglycerol)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Oxygen (Dioxygen)IBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 01/2019

Therapy/Procedure

17	Therapeutics 08/2022 - 09/2014
2	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2019 - 01/2019
1	Subcutaneous Injections 01/2022
1	Surgical Amputation (Amputations) 01/2020
1	Intravenous Infusions 01/2020
1	Precision Medicine 01/2020
1	Percutaneous Coronary Intervention 01/2019
1	Injections 11/2014